Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, of any race, at least 18 years of age (inclusive).~* Freely provides both verbal and written informed consent.~* Has an area of plaque psoriasis appropriate for topical treatment that covers a body surface area (BSA) of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this calculation.~* Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.~* Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this assessment).~Exclusion Criteria:~* Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the Investigator.~* Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the Investigator.~* Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the Investigator.~* Is pregnant, nursing an infant, or planning a pregnancy during the study period.~* Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit or is concurrently participating in another clinical study with an investigational drug or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDP-122 Lotion (Type: EXPERIMENTAL): Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks.
- IDP-122 Vehicle Lotion (Type: PLACEBO_COMPARATOR): Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).